Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2
ALA exerts potent anti-DEL activity by simultaneously targeting GSK3β in the Wnt pathway and directly inhibiting BCL2, leading to suppressed tumor proliferation and induced apoptosis. Our findings highlight ALA as a promising multi-targeting therapeutic candidate for DEL and propose a novel strategy against this refractory lymphoma.
Authors
- Chunyang Zhou (ORCID: https://orcid.org/0000-0001-7925-9178)
- Sha Yang
- Jiaojiao Bian
- Chunlei Yu (ORCID: https://orcid.org/0000-0002-2934-2122)
- Zhengmin Xu
- Dazhang Bai (ORCID: https://orcid.org/0000-0002-9475-5003)
- Lu Zhao (ORCID: https://orcid.org/0000-0002-8055-5211)
- Qing Liao (ORCID: https://orcid.org/0009-0005-8567-1982)
- Jianhua Chen
- Xianfu Li (ORCID: https://orcid.org/0000-0002-1258-1573)
- Dan Wen (ORCID: https://orcid.org/0000-0002-5503-1213)
Institutions
- North Sichuan Medical University (CN)
- People’s Hospital of Wenshan Prefecture (CN)
- Affiliated Hospital of North Sichuan Medical College (CN)
- Sichuan Center for Disease Control and Prevention (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Blood and Lymphatic Cancer Targets and Therapy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/blctt.s556751
- Primary Topic
- Wnt/β-catenin signaling in development and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sichuan University